Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
SFR 0.370 +68.2% OMM 0.050 +0.0% EMO 0.340 −1.4% GGA 5.55 +4.7% MDM 0.060 +0.0% WGX 4.33 −2.3% FL 0.410 +0.0% SSRM 36.32 −0.1% CD 0.240 +4.3% GEN 0.065 −7.1% ALS 56.12 −2.3% LIFT 3.14 −0.3% NTR 94.34 +0.1% ICON 0.045 +0.0% LMG 0.450 +0.0% NZP 0.045 −10.0% SFR 0.370 +68.2% OMM 0.050 +0.0% EMO 0.340 −1.4% GGA 5.55 +4.7% MDM 0.060 +0.0% WGX 4.33 −2.3% FL 0.410 +0.0% SSRM 36.32 −0.1% CD 0.240 +4.3% GEN 0.065 −7.1% ALS 56.12 −2.3% LIFT 3.14 −0.3% NTR 94.34 +0.1% ICON 0.045 +0.0% LMG 0.450 +0.0% NZP 0.045 −10.0%

Healthcare

Page 103
  1. Nov 13, 2025 · 16:08 · FRX

    Fennec Pharmaceuticals Announces Proposed Offering of Common Shares

    Fennec Pharmaceuticals Announces Proposed Offering of Common Shares

    01
  2. Nov 13, 2025 · 16:05 · PRN

    Profound Medical Reports Strong Third Quarter 2025 Financial Results

    Profound Medical Reports Strong Third Quarter 2025 Financial Results

    02
  3. Nov 13, 2025 · 16:01 · FRX

    Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

    Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

    03
  4. Nov 13, 2025 · 16:01 · VITA

    Vitalist Reports Second Quarter 2026 Financial Results

    Vitalist Reports Second Quarter 2026 Financial Results

    04
  5. Nov 13, 2025 · 10:57 · HEM

    Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway

    Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway

    05
  6. Nov 13, 2025 · 10:51 · 4151

    Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI(TM) (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

    Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI(TM) (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

    06
  7. Nov 13, 2025 · 08:40 · MBIO

    MindBio Therapeutics Announces Results from Landmark Phase 2B Microdosing in Depression Trail

    MindBio Therapeutics Announces Results from Landmark Phase 2B Microdosing in Depression Trail

    07
  8. Nov 13, 2025 · 07:46 · CRDL

    Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

    Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

    08
  9. Nov 13, 2025 · 07:30 · NPTH

    NEUPATH HEALTH REPORTS THIRD QUARTER 2025 RESULTS

    NEUPATH HEALTH REPORTS THIRD QUARTER 2025 RESULTS

    09
  10. Nov 13, 2025 · 07:01 · WELL

    WELL Health Provides Corporate Update on WELLSTAR Reflecting Organic and Inorganic Growth Wins

    WELL Health Provides Corporate Update on WELLSTAR Reflecting Organic and Inorganic Growth Wins

    10
  11. Nov 13, 2025 · 07:01 · SVA

    Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts

    Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts

    11
  12. Nov 13, 2025 · 07:00 · MDNA

    Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

    Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

    12
  13. Nov 13, 2025 · 07:00 · BLCO

    Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day

    Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day

    13
  14. Nov 13, 2025 · 06:30 · HLS

    HLS Therapeutics Announces Q3 2025 Financial Results

    HLS Therapeutics Announces Q3 2025 Financial Results

    14
← Newer Older →